Navigation Links
Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
Date:7/14/2014

g cells and generally have a lower probability of tumor kill. Anti-Angiogenesis compounds typically offer limited survival benefits and cause serious side effects.
  • GenSpera's drug candidates are based on chemical derivatives of a plant cytotoxin, called Thapsigargin, which is a potent inhibitor of the intracellular sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) pump. The inhibition of the transport protein causes intracellular Ca2+ (calcium) to rise significantly and trigger apoptosis (cell death). GenSpera masks Thapsigargin's toxicity in the blood stream and delivers and activates it only at the tumor site. 
  • GNSZ's lead candidate, G-202, should be useful against most tumor types. Its first targeted indication is liver cancer, the third largest cancer killer worldwide. G-202 is a prodrug where the active cytotoxin, 12ADT, is masked by a peptide complex until it binds to and cleaved by the targeted Prostate-Specific Membrane Antigen (PSMA), thus triggering apoptosis. Nexavar®, currently the only approved drug for this indication, has more than $700 million in annual sales.
  • G-202 is showing excellent clinical results with Phase IB and early Phase II data in liver cancer, highly suggestive of clinical activity. Only a few easily managed and predictable side effects in Phase 1 were observed. Early Phase II data look promising with a benign side-effect profile and impressive clinical results in advanced liver cancer patients. Phase II clinical trial in liver cancer is ongoing. GNSZ is now using DCE-MRI imaging on newly-enrolled patients (in addition to X-ray), both at baseline and after treatment intervals that the company thinks could demonstrate the decreased blood flow to the tumor, and, thus, the successful killing of the cancerous cells. Typically in this very advanced liver cancer population, the shrinkage of the tumors are not visible on the X-rays due to intense scarring of the tissues.
  • GenSpera's seco
    '/>"/>

  • SOURCE GenSpera, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. CVS Caremark Corporation Announces Quarterly Dividend
    2. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
    3. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
    4. Volcano Corporation Announces Preliminary Fourth Quarter 2013 Revenues; Year-Over-Year Annual Revenues Increase Eight Percent On A Constant Currency Basis
    5. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
    6. Heska Corporation to Present at the Sidoti Semi-Annual Micro-Cap Conference
    7. Ramon Martinez Named President of Comprehensive Care Corporation and Elected to the Companys Board of Directors
    8. Dynasil Corporation of America Reports Fiscal Year 2013 Financial Results
    9. Ormco Corporation Files Appeal to the Federal Court Against Ortho Classic H4 Bracket Patent Infringement
    10. EPGL Technology Selected by Major Corporation for Development
    11. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... , Spanien, September 23, 2014 ... dass sich Fernzugriffe auf eTMF im Jahr ... ermöglicht den Sponsoren von klinischen Versuchsreihen, die ... und Vollständigkeit von Stammdateien mit Informationen über ... zu erfüllen     Die bisher ...
    (Date:9/22/2014)... 22, 2014 Levi & Korsinsky is investigating ... "the Company") (NasdaqGS: SIAL ) for possible ... law in connection with the sale of the Company ... to learn more about the investigation: http://zlkdocs.com/SIAL-Info-Request-Form_ma-2199 , ... to you. Under the terms of the ...
    (Date:9/22/2014)... , Sept. 22, 2014 Avanir Pharmaceuticals, ... it is offering to sell $200 million of its ... Deutsche Bank Securities and BofA Merrill Lynch are acting ... grant the underwriters a 30-day option to purchase additional ... to be sold in the offering are being sold ...
    Breaking Medicine Technology:Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 2Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 3Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 4Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 5SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
    ... S.C., Sept. 9 At approximately 3:21,PM ... Chairman and Founder of,CureHIV.us, agreed to act ... Global,Humanceuticals, Inc,s., new extremely effective, safe and ... non-government, U.S.,and foreign institutions, organizations, and corporations, ...
    ... Effective Antibiotics Against ,Superbugs, BOSTON, Sept. 6 ... may have discovered the path,toward developing better drugs ... resistance to common antibiotics. The,researchers have discovered a ... opens to door to new avenues of research., ...
    Cached Medicine Technology:Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 3
    (Date:9/23/2014)... September 23, 2014 Steven Winter Associates, ... firm’s recent projects in the State of Connecticut – ... Gateway at 570 – were honored by the Connecticut ... Awards held on September 18, 2014 at Stepping Stones ... High School, Bridgeport , Recipient of the Institutional Award ...
    (Date:9/23/2014)... (PRWEB) September 23, 2014 ... of 3.7 out of 5, indicating moderate buyer ... portable and range from basic household carbon monoxide ... gas concentrations in parts per million. Buyers benefit ... choice of many suppliers, especially amongst distributors,” according ...
    (Date:9/23/2014)... (PRWEB) September 23, 2014 Ale Gicqueau, ... presenting on Advanced Data Visualization for Clinical Trials at ... SDE in San Francisco on Friday, September 26, 2014. ... by volunteers. Since its inception, PhUSE has expanded from ... to a global platform for the discussion of topics ...
    (Date:9/23/2014)... With the emergence of CVS Health and its ... retail chains are transforming the healthcare landscape to provide ... shoppers. In this capacity, Inside Pharmacy™ is a forum ... share their knowledge on patient care, achieve professional success, ... with other colleagues inside the pharmacy. , This latest ...
    (Date:9/23/2014)... September 23, 2014 Published by Nationwide Lifts, ... issues to take charge of their mobility in a new ... positively impactful. Stair lifts are that equipment and ... “Being in the elevator business, I’ve seen so ... themselves or a loved one with mobility issues,” said Andy ...
    Breaking Medicine News(10 mins):Health News:Steven Winter Associates’ Projects Receive 2014 Green Building Awards 2Health News:Steven Winter Associates’ Projects Receive 2014 Green Building Awards 3Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 2Health News:Gas Detectors Procurement Category Market Research Report Now Available from IBISWorld 3Health News:Clinovo Sponsors and Presents at Pharmaceutical Users Software Exchange (PhUSE) SDE in San Francisco 2Health News:Retail Pharmacies at the Forefront of Primary Care Innovation 2Health News:Nationwide Lifts, America’s Leader in Home Elevators, Is Proud to Announce the Release of Its First Book, “Stair Lifts: Move Up, Not Out!” 2
    ... when therapy goes to more than just severe cases, ... Pregnant women who receive treatment for the mildest forms ... self-monitoring of blood glucose levels and possibly insulin therapy ... or develop preeclampsia or high blood pressure during pregnancy, ...
    ... ... Kraft , ... September 30, 2009 -- The Boston biotechnology industry will get an early look at biotech,s ... 27, 2009 at Harvard Medical School. , , ,At the one-day event, recently funded companies ...
    ... children don,t see their family dentist until they are well ... both dental and medical professionals. , That,s one of the ... conducted on behalf of Delta Dental Plans Association, the nation,s ... gain greater knowledge about the state of children,s oral health. ...
    ... Incorporated (NYSE: HR ) announced it has entered into ... previous $400 million facility. The new facility includes 16 ... priced at 2.80% over LIBOR, with a 0.40% facility fee, ... loans of this nature. , Healthcare Realty Trust ...
    ... TOLEDO, Ohio, Sept. 30 Heartland Information Services, a ... Brett S. Himes to President and Chief Executive Officer. ... will assume the President and CEO position immediately. , ... C. Cirino, who has accepted a new position with ...
    ... Walter and Eliza Hall Institute researchers have put an ... a molecular messenger called Fas ligand is responsible for ... Apoptosis is an important process in human biology ... bodies, protecting us against cancer development and diseases where ...
    Cached Medicine News:Health News:Study Urges Treatment for Even Mild Gestational Diabetes 2Health News:Study Urges Treatment for Even Mild Gestational Diabetes 3Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 2Health News:Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery 3Health News:Delayed First Visit to Dentist Can Affect Children's Lifelong Oral Health 2Health News:Healthcare Realty Trust Announces New $550 Million Unsecured Revolving Credit Facility 2Health News:Heartland Information Services Appoints New Chief Executive Officer 2Health News:Research puts a 'Fas' to the cause of programmed cell death 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: